Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic Cardiovascular Disease and Type 2 diabetes: insights from the Department of Veterans affairs
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al
Semaglutide 2.4 mg was associated with a statistically significant 8% increase in paracetamol AUC 05h versus placebo, which might be partially explained by substantially lower body weight in the semaglutide group compared with placebo at week 20 (greater body weight is associated with reduced paracetamol absorption rates and increased clearance 32 , 33 )
63 The authors assessed the external validity of the SF-36 by comparing the scale scores at the start of diabetes therapy and education and 4 weeks after completion with the Well-Being Questionnaire, the Diabetes Treatment Satisfaction Questionnaire, the Diabetes, and the Quality of Life with Diabetes questionnaire
Book a free virtual consultation today and let us help you create a plan that fits your lifestyle and goals